Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
InCube Ventures, LLC is a venture capital firm founded in 2008, with dual headquarters in Silicon Valley and San Antonio. As the venture arm of InCube Labs, a research and development lab dedicated to life sciences, InCube Ventures focuses on investing in and nurturing companies that tackle significant clinical challenges. The firm manages multiple funds, including DFJ InCube Ventures, in collaboration with Draper Fisher Jurvetson.
InCube Ventures has built a reputation for its commitment to breakthrough innovations in life sciences, particularly in pharmaceuticals, biologics, and medical devices. The firm has a portfolio of 10 companies, reflecting its strategy of investing across various stages, from pre-seed to Series C. Notable milestones include successful exits such as IPOs and acquisitions, showcasing the firm's ability to identify and support transformative healthcare solutions.
InCube Ventures specializes in early, mid, and late-stage investments in life sciences companies. The firm primarily focuses on sectors such as pharmaceuticals, biologics, and medical devices, with a particular emphasis on breakthrough innovations that can significantly impact patient care. InCube Ventures seeks to address unmet clinical needs for large patient populations, steering clear of incremental advancements.
The firm invests in a diverse range of therapeutic areas, including neurovascular treatments, chronic pain management, gastrointestinal therapeutics, oral peptide and protein delivery, and iron-deficiency anemia. InCube Ventures' investment thesis is clear: they prioritize transformative solutions that can set new standards of care, rather than supporting companies that only offer incremental improvements.
InCube Ventures has a notable portfolio of companies that exemplify its focus on breakthrough innovations in life sciences. Key portfolio companies include:
InCube Ventures has successfully facilitated multiple exits, including IPOs for Rani Therapeutics and Metagenomi, and acquisitions for several other portfolio companies, demonstrating its effectiveness in identifying and nurturing high-potential startups.
Mir Imran: Founder of InCube Ventures, Mir Imran is a prolific medical inventor and entrepreneur with over 20 founded companies and more than 400 issued or pending US patents. His expertise lies in life sciences and medical technology.
Andrew Farquharson: Team member with experience in venture capital and life sciences, contributing to the firm's investment strategy and portfolio management.
Talat Imran: Team member focused on supporting portfolio companies and enhancing their growth potential through strategic guidance.
Mark Sieczkarek: Team member with a background in healthcare investments, providing insights into market trends and opportunities.
Wayne Roe: Team member involved in operational support and resource allocation for portfolio companies.
Startups interested in pitching to InCube Ventures should send their proposals via email to info@incubevc.com. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. Founders should expect a response within a few weeks, and warm introductions are preferred but not mandatory.
InCube Ventures has been actively nurturing its portfolio of life sciences companies, including notable firms like Metagenomi and WhiteSwell. The firm emphasizes identifying and supporting innovations that set new standards of care. Recent activity includes successful exits for several portfolio companies, showcasing the firm's effectiveness in the venture capital space.
In 2023, InCube Ventures celebrated the IPOs of both Rani Therapeutics and Metagenomi, marking significant milestones in its investment history. The firm continues to explore new opportunities in the life sciences sector, focusing on transformative healthcare solutions.
What are InCube Ventures' investment criteria?
InCube Ventures invests in early, mid, and late-stage life sciences companies, focusing on pharmaceuticals, biologics, and medical devices. The firm seeks breakthrough innovations that address unmet clinical needs for large patient populations.
How can startups apply or pitch to InCube Ventures?
Startups can reach out to InCube Ventures via email at info@incubevc.com. It is advisable to include a detailed pitch deck outlining the business model, market opportunity, and team background.
What makes InCube Ventures different from other VC firms?
InCube Ventures emphasizes transformative healthcare solutions rather than incremental improvements. The firm leverages its extensive network in the life sciences sector and resources from InCube Labs to support portfolio companies.
What is the geographic scope of InCube Ventures?
The firm primarily invests in companies based in the United States, with a focus on Silicon Valley and San Antonio.
What is the typical check size for investments?
InCube Ventures invests across various stages, including pre-seed, seed, seed-plus, Series A, Series B, and Series C, though specific check sizes are not publicly disclosed.
What kind of post-investment involvement does InCube Ventures have?
The firm actively supports its portfolio companies in navigating clinical development, regulatory pathways, and commercialization strategies, leveraging its deep industry expertise.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.